Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

被引：137
|
作者：
Soverini, Simona [1 ]
Branford, Susan [2 ,3 ,4 ]
Nicolini, Franck E. [1 ,5 ]
Talpaz, Moshe
Deininger, Michael W. N. [6 ]
Martinelli, Giovanni [1 ]
Mueller, Martin C. [7 ]
Radich, Jerald P. [8 ]
Shah, Neil P. [9 ]
机构：
[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] SA Pathol, Dept Mol Pathol, Ctr Canc Biol, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia
[5] Ctr Hosp Lyon Sud, Hematol Dept 1G, F-69310 Pierre Benite, France
[6] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[7] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[9] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期
关键词：
BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations; DIAGNOSED CHRONIC-PHASE; BCR-ABL MUTATIONS; DASATINIB; 100; MG; PHILADELPHIA-POSITIVE PATIENTS; GIMEMA WORKING PARTY; IMATINIB-RESISTANT; FOLLOW-UP; HIGH-RISK; CML; CHROMOSOME;
D O I：
10.1016/j.leukres.2013.09.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：10 / 20
页数：11
相关论文
共 50 条
  • [21] Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
    Baccarani, Michele
    Rosti, Gianantonio
    Soverini, Simona
    LEUKEMIA, 2019, 33 (10) : 2358 - 2364
  • [22] Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Eide, Christopher A.
    Bottomly, Daniel
    Savage, Samantha L.
    White, Libbey
    Wilmot, Beth
    Schultz, Anna M. Reister
    Uchida, Kimberly A.
    Agarwal, Anupriya
    Traer, Elie
    Beppu, Lan
    Sala-Torra, Olga
    Radich, Jerald P.
    Eickelberg, Garrett
    Press, Richard D.
    Loriaux, Marc M.
    Tantravahi, Srinivas K.
    Pomicter, Anthony D.
    Zabriskie, Matthew S.
    Deininger, Michael W.
    O'Hare, Thomas
    Tyner, Jeffrey W.
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    BLOOD, 2016, 128 (22)
  • [23] Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
    Michele Baccarani
    Gianantonio Rosti
    Simona Soverini
    Leukemia, 2019, 33 : 2358 - 2364
  • [24] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
    Kihel, I.
    Nachi, M.
    Cayuela, J.
    Bekadja, M. A.
    Note, A.
    CLINICA CHIMICA ACTA, 2024, 558
  • [25] Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia
    Gibbons, Don L.
    Pricl, Sabrina
    Posocco, Paola
    Laurini, Erik
    Fermeglia, Maurizio
    Talpaz, Moshe
    Cortes, Jorge E.
    Donato, Nicholas J.
    Quintas-Cardama, Alfonso
    BLOOD, 2013, 122 (21)
  • [26] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Eiring, A. M.
    Khorashad, J. S.
    Anderson, D. J.
    Yu, F.
    Redwine, H. M.
    Mason, C. C.
    Reynolds, K. R.
    Clair, P. M.
    Gantz, K. C.
    Zhang, T. Y.
    Pomicter, A. D.
    Kraft, I. L.
    Bowler, A. D.
    Johnson, K.
    Mac Partlin, M.
    O'Hare, T.
    Deininger, M. W.
    LEUKEMIA, 2015, 29 (12) : 2328 - 2337
  • [27] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    A M Eiring
    J S Khorashad
    D J Anderson
    F Yu
    H M Redwine
    C C Mason
    K R Reynolds
    P M Clair
    K C Gantz
    T Y Zhang
    A D Pomicter
    I L Kraft
    A D Bowler
    K Johnson
    M Mac Partlin
    T O'Hare
    M W Deininger
    Leukemia, 2015, 29 : 2328 - 2337
  • [28] Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
    Claudiani, Simone
    Apperley, Jane F.
    Khan, Afzal
    Khorashad, Jamshid
    Milojkovic, Dragana
    HAEMATOLOGICA, 2020, 105 (05) : E225 - E227
  • [29] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
  • [30] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
    Kim, Sung-Hyun
    Menon, Hari
    Jootar, Saengsuree
    Saikia, Tapan
    Kwak, Jae-Yong
    Sohn, Sang-Kyun
    Park, Joon Seong
    Jeong, Seong Hyun
    Kim, Hyeoung Joon
    Kim, Yeo-Kyeoung
    Oh, Suk Joong
    Kim, Hawk
    Zang, Dae Young
    Chung, Joo Seop
    Shin, Ho Jin
    Do, Young Rok
    Kim, Jeong-A
    Kim, Dae-Young
    Choi, Chul Won
    Park, Sahee
    Park, Hye Lin
    Lee, Gong Yeal
    Cho, Dae Jin
    Shin, Jae Soo
    Kim, Dong-Wook
    HAEMATOLOGICA, 2014, 99 (07) : 1191 - 1196
12345